Erasca, Inc.
ERAS
Rank in Stocks
#3573
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Share Price
$13.68
Last synced: 2026-10-19
Market Cap
$4.78B
Change (1 day)
2.13%
Change (1 year)
455.89%
Country
US
Trade Erasca, Inc. (ERAS)
Category
Healthcare
P/B ratio for Erasca, Inc. (ERAS)
P/B ratio as of October 2026 TTM: 12.65
According to Erasca, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 12.65. At the end of 2023 the company had a P/B ratio of 1.01.
P/B ratio history for Erasca, Inc. from 2019 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 12.65 | 809.88% |
| 2024 | 1.39 | 37.19% |
| 2023 | 1.01 | -20.90% |
| 2022 | 1.28 | -68.58% |
| 2021 | 4.06 | -122.34% |
| 2020 | -18.19 | -88.07% |
| 2019 | -152.41 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -50.57% |
US
|
|
| 13.2547 | 4.80% |
US
|
|
| 4.208 | -66.73% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -51.12% |
NL
|
